We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Great update today confirms all the recent goings on GSK etc and trading ahead of board expectations.
Chippenham, UK - 12 January 2021: Vectura Group plc (LSE: VEC) ("Vectura" or "the Group"), an industry-leading specialist inhalation CDMO, today announces an unaudited 2020 pre-close trading update. The Group expects revenue and Adjusted EBITDA for 2020 to be ahead of Board expectations, following Q4 2020 approval of VR315 (US), generic Advair®, partnered with Hikma.
Mister markets response yea its just what we expected.
Must be a take out target at this price plus the 200 mill +interest and the Hikma payments
Without Skyepharma ??
Miles to cheap GSK could pick them up and get there fined back lol
That is great news and takes the uncertainty away that this saga was going to drag on for a while longer, the strength that this cash adds to the balance sheet along with our recent $11m stage payment puts us in a very enviable position, what I wonder are we going to do with it? Hopefully not fritter some of it away on meaningless share buybacks, instead look for a nice cash generating bolt on acquisition.
was expecting a greater sp rise as this is worth circa 20% of our mcap imv.
RNS out - payment in full by end of Jan 2021. ~$200m
Payment in full by end of Jan 2021.
Great timing MG & with confirmation of GSK s capitulation & a positive trading update early next month ,including ,hopefully ,reference to our projected Advair royalties & confirmation that our CDMO policy continues to gather momentum ,our SP could rapidly approach previous highs ,having performed poorly since MH SKP shares were acquired .
I've taken a position today:
hTTps://twitter.com/MGinvestor/status/1342046539917778944?s=20
It is also my top 5 pick for the 2021 Stocko challenge:
hTTps://twitter.com/MGinvestor/status/1342050477832347655?s=20
Submit yours too.
Look forward to contributing here
It's looking good for VEC and when the cash lands I hope they will look at an acquisition to add more growth to what we already have and what is already coming to fruition, when the right downs finally stop from the SKP merger it will be more obvious to to the casual observer that VEC has always been cash generating but the headline loss is what catches the eye unless you dig a little deeper.
Prospects looking bright for 2021.
Hopefully GSK are about to publicly capitulate ?
Manufactured drop, GSK rattling the cage for a cheap takeover?
Hopefully it will confirmed on Monday that GSK have not appealed to The Supreme Court & the trading update due early next month will be positive,possibly indicate how our substantial cash pile will be used & confirm progress in respect of our CDMO business .I have held (& bought)since SKP but for the first time since then I believe that a serious re rating could take place over the near term & with continued positive news could exceed 150p fairly soon with 200p in the horizon too .My concern is that having acquired a poorly performing company(from a SP perspective) by default I would be disappointed if an opportunist bid took us out too soon as this time next year our prospects could be perceivable much brighter
To be honest. I'm really surprised at the minimal number of BB participants here....it says to me this is very much under the radar until the chartists and IIs see the underlying SP trend that is now firmly established. All is good here its better for a 2% rise every week as folks figure the upside opportunity and the M&A possibilities with good bid premiums and the possibilities of Synairgen catalysing the interest in direct to lung drug applications .
There was very little in our SP for Advair & additional annualised profits of $50-$100mill is not insubstantial & in itself should be worth $750-$1bill , ie over £1 per share.
If GSK dont appeal today it will be interesting to see what value our brokers put on us & I wouls expect a strong buy as there is also no value ascribed to our new CDMO business-which is likely to be more successful than anticipated by many.The value of our Ellipta range generics could exceed Advair.
This is fantastic news, now only waiting on GSK to see what they decide to do, last day for filing an appeal to the supreme court.
Still Too cheap
Target 150pence
With 200 pence Early next year
Apologies - just realised I missed yesterdays thread....
Still no harm in flagging it again!
FDA approval-
Vectura Group plc (LSE: VEC) ("Vectura"), an industry-leading specialist inhalation CDMO, today announces that its partner Hikma Pharmaceuticals has launched its generic version of GlaxoSmithKline's Advair Diskus®1 (fluticasone propionate and salmeterol inhalation powder), 100mcg/50mcg and 250mcg/50mcg doses, in the US. The launch of the product follows approval by the US Food and Drug Administration (FDA)
If Gsk buy us it will have to be at a fair price,which would be likely to exceed 200p & would reflect the value of their loss,assuming they don't appeal to the Senate tomorrow.Meanwhile after today's news our SP should enjoy the long awaited rerating
The settlement belongs to Vectura management not shareholders, they will dictate where the money goes. If GSK buy vectura before they have to pay the settlement they have technically have saved themselves $200 million dollars, especially as it is not really recognised in the current share price. The FDA announcement will add fuel to the fire.
Don’t get the buy out comment, the settlement belongs to the shareholders so it would be settlement + value of Vectura to buy us out?
Did you read Hikma release. This is a $2 billion brand, so If Hikma pick up 10%, that’s $30m royalty to Vectura. Royalty is straight to bottom line, not revenue!!
Following this fantastic news , & earlier than expected, should GSK concede tomorrow our SP should be very strong & hopefully recovering towards the highs when my SKP shares were acquired.Mid teen % royalty should see an immediate improvement in both our top & bottom lines -apart from our rapidly growing cash pile .I hope our CEO has bolt on acquisition targets in mind in order to escalate the growth in his CDMO project - apart from the possibility of buy backs, a special dividend & the possibility of a progressive dividend policy
I wonder when GSK are going to put a bid in for us? They only have tomorrow to contest the court case also. Thats another $200million or so. ReRate cominggggggg
At long, long last!